
TNDM Stock Forecast & Price Target
TNDM Analyst Ratings
Bulls say
Tandem Diabetes Care has successfully positioned itself in the insulin pump market since its 2012 entry, with its product lineup now including the advanced t:slim X2 and the recently launched Mobi pump, indicating ongoing innovation and product development. Approximately 75% of the company’s revenue comes from the United States, where its durable insulin pumps and disposable infusion sets account for a significant portion of total sales, reflecting a strong customer base and recurring revenue model. Despite facing increased competition and a need to retain customers, the firm maintains its revenue estimates, showcasing confidence in sustained growth potential amid market dynamics.
Bears say
Tandem Diabetes Care has consistently reported significant operating losses since its inception, raising concerns about its ability to achieve sustained profitability in the future. Furthermore, uncertainty in global economic and political conditions introduces additional risks that could hinder the company's ability to predict product demand, thereby negatively impacting financial results. Although there are expectations of achieving positive adjusted EBITDA by Q3 2025, the projected slower ramp in profitability due to increased investments in commercial infrastructure presents further challenges for the company's financial outlook.
This aggregate rating is based on analysts' research of Tandem Diabetes Care and is not a guaranteed prediction by Public.com or investment advice.
TNDM Analyst Forecast & Price Prediction
Start investing in TNDM
Order type
Buy in
Order amount
Est. shares
0 shares